Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vopimetostat · TNG462

Small molecule · Inhibitor of PRMT5 · developed by Tango Therapeutics

Phase 1/2 Most advanced trial
TNGX Developer
3 Registered trials

What is Vopimetostat?

Vopimetostat (TNG462) is an orally bioavailable small molecule that selectively binds and inhibits PRMT5, a methyltransferase that adds methyl groups to histone and other protein arginine residues. It is designed to be especially active in MTAP-deleted cancer cells, and is being studied in solid tumors including pancreatic ductal adenocarcinoma and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TNG462
Drug type
Small molecule
Targets
PRMT5, MTAP (biomarker)
Mechanism
Inhibitor of PRMT5
Pathways
histone arginine methylation, gene expression regulation of cell proliferation
Therapy area
Oncology
Developer
Tango Therapeutics, Inc. (TNGX)
Also in trials of
RVMD
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
54P82QYL4L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07897734 Phase 1/2 PDAC Not yet recruiting TNGX
NCT06922591 Phase 1/2 PDAC Recruiting RVMD
NCT05732831 Phase 1/2 Locally Advanced Solid Tumor Recruiting TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced Solid TumorLung CancerMTAP DeletionNSCLCPancreatic Cancer MetastaticPDACPDAC - Pancreatic Ductal AdenocarcinomaRAS MutationThoracic Cancer

Other drugs acting on PRMT5

More from Tango Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.

Follow TNGX, the company behind Vopimetostat

See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.